- November 17, 2019
- Category: Healthcare and LifeSciences, Medical Diagnostics
Global Neurotrophic Keratitis Market Size study, by Treatment Type (Preservative Free Artificial Tears, Topical Antibiotics, Amniotic Membrane Transplantation, Tarsorrhaphy, Recombinant Human Nerve Growth Factor (rhNGF), Others) and Regional Forecasts 2020-2026
Chapter 1. Executive Summary 1.1. Market Snapshot 1.2. Global & Segmental Market Estimates & Forecasts, 2018-2026 (USD Million) 1.2.1. Neurotrophic Keratitis Market, by Region, 2018-2026 (USD Million) 1.2.2. Neurotrophic Keratitis Market, by Treatment Type, 2018-2026 (USD Million) 1.3. Key Trends 1.4. Estimation Methodology 1.5. Research Assumption Chapter 2. Global Neurotrophic Keratitis Market Definition and Scope 2.1. Objective of the Study 2.2. Market Definition & Scope 2.2.1. Scope of the Study 2.2.2. Industry Evolution 2.3. Years Considered for the Study 2.4. Currency Conversion Rates Chapter 3. Global Neurotrophic Keratitis Market Dynamics 3.1. Neurotrophic Keratitis Market Impact Analysis (2018-2026) 3.1.1. Market Drivers 3.1.2. Market Challenges 3.1.3. Market Opportunities Chapter 4. Global Neurotrophic Keratitis Market Industry Analysis 4.1. Porterâ€™s 5 Force Model 4.1.1. Bargaining Power of Suppliers 4.1.2. Bargaining Power of Buyers 4.1.3. Threat of New Entrants 4.1.4. Threat of Substitutes 4.1.5. Competitive Rivalry 4.1.6. Futuristic Approach to Porterâ€™s 5 Force Model (2016-2026) 4.2. PEST Analysis 4.2.1. Political 4.2.2. Economical 4.2.3. Social 4.2.4. Technological 4.3. Investment Adoption Model 4.4. Analyst Recommendation & Conclusion Chapter 5. Global Neurotrophic Keratitis Market, by Treatment Type 5.1. Market Snapshot 5.2. Global Neurotrophic Keratitis Market by Treatment Type, Performance - Potential Analysis 5.3. Global Neurotrophic Keratitis Market Estimates & Forecasts by Treatment Type 2016-2026 (USD Million) 5.4. Neurotrophic Keratitis Market, Sub Segment Analysis 5.4.1. Preservative Free Artificial Tears 5.4.2. Topical Antibiotics 5.4.3. Amniotic Membrane Transplantation 5.4.4. Tarsorrhaphy 5.4.5. Recombinant Human Nerve Growth Factor (rhNGF) 5.4.6. Others Chapter 6. Global Neurotrophic Keratitis Market, Regional Analysis 6.1. Neurotrophic Keratitis Market, Regional Market Snapshot 6.2. North America Neurotrophic Keratitis Market 6.2.1. U.S. Neurotrophic Keratitis Market 22.214.171.124. Treatment Type breakdown estimates & forecasts, 2016-2026 6.2.2. Canada Neurotrophic Keratitis Market 6.3. Europe Neurotrophic Keratitis Market Snapshot 6.3.1. U.K. Neurotrophic Keratitis Market 6.3.2. Germany Neurotrophic Keratitis Market 6.3.3. Rest of Europe Neurotrophic Keratitis Market 6.4. Asia-Pacific Neurotrophic Keratitis Market Snapshot 6.4.1. China Neurotrophic Keratitis Market 6.4.2. India Neurotrophic Keratitis Market 6.4.3. Japan Neurotrophic Keratitis Market 6.4.4. Rest of Asia Pacific Neurotrophic Keratitis Market 6.5. Latin America Neurotrophic Keratitis Market Snapshot 6.5.1. Brazil Neurotrophic Keratitis Market 6.5.2. Mexico Neurotrophic Keratitis Market 6.6. Rest of The World Neurotrophic Keratitis Market Chapter 7. Competitive Intelligence 7.1. Top Market Strategies 7.2. Company Profiles 7.2.1. Allergan, Plc. 126.96.36.199. Key Information 188.8.131.52. Overview 184.108.40.206. Financial (Subject to Data Availability) 220.127.116.11. Product Summary 18.104.22.168. Recent Developments 7.2.2. Abbott Laboratories, Inc. 7.2.3. Bausch & Lomb Incorporated 7.2.4. Bayer AG 7.2.5. CooperVision 7.2.6. Dompe farmaceutici S.p.A. 7.2.7. Johnson & Johnson 7.2.8. Novartis AG 7.2.9. ReGenTree, LLC. 7.2.10. Walgreens Chapter 8. Research Process 8.1. Research Process 8.1.1. Data Mining 8.1.2. Analysis 8.1.3. Market Estimation 8.1.4. Validation 8.1.5. Publishing 8.2. Research Attributes 8.3. Research Assumption
Global Neurotrophic Keratitis Market is valued approximately USD 92 million in 2019 and is anticipated to grow with a healthy growth rate of more than 17% over the forecast period 2019-2026. Neurotrophic Keratitis (NK) is a neurodegenerative disease caused by the injury of trigeminal nerve that affects the cornea of an eye. In this disease, the patient drops the corneal sensitivity and thus cornea is unprotected to damages without treatment. If this disease is not treated and diagnosed properly, the patient can loss permanent eye vision. The treatment of neurotrophic keratitis is done by a team that includes neurologists, ophthalmologists and corneal specialists. Treatments are available based on the severity of the disease. Neurotrophic Keratitis treatment comprises topical antibiotics, bandage contact lenses, preservative artificial tears, amniotic membrane transplantation, keratoplasty, Recombinant human nerve growth factor (rhNGF), and so on. Growing number of approvals for new product innovation from regulatory authorities, with the huge financial support to the researchers for developing novel treatments are the few factors responsible for high CAGR of the market over the forecast period. For instance, in August 2018, Dompe farmaceutici S.p.A. has received approval for cenegermin topical eyes drop from FDA, which is a recombinant human nerve growth factor for the therapy of neurotrophic keratitis. The cenegermin has also obtained an Orphan Drug designation, Breakthrough Therapy designation and Fast Track status from the FDA. This, in turn, is expected to accelerate the growth of Neurotrophic Keratitis market around the world. However, low healthcare budget in some of the developing countries is one of the major factors expected to hamper the growth of the market over the forecast period of 2020-2026.
The regional analysis of global Neurotrophic Keratitis market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the rising product approvals, presence of well-established healthcare infrastructure, and increase in R&D activities in neurotrophic keratitis in the region. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2020-2026, due to growing geriatric population and increasing government investments in healthcare and R&D present in the countries like China and India.
Major market player included in this report are:
Abbott Laboratories, Inc.
Bausch & Lomb Incorporated
Dompe farmaceutici S.p.A.
Johnson & Johnson
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Treatment Type:
Preservative Free Artificial Tears
Amniotic Membrane Transplantation
Recombinant Human Nerve Growth Factor (rhNGF)
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year â€“ 2016, 2017, 2018
Base year â€“ 2019
Forecast period â€“ 2020 to 2026
Target Audience of the Global Neurotrophic Keratitis Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Value-Added Resellers (VARs)
Third-party knowledge providers